Dingwei Ye

机构：Beijing Institute of Technology, Shanghai Medical College of Fudan University, Fudan University Shanghai Cancer Center, Shanghai Cancer Institute · ORCID：0000-0003-4974-3780

发表论文 315 篇 · 总被引 11114 次 · h-index 38

代表论文

• ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (2025 · New England Journal of Medicine · 被引 143)
• Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial (2025 · Nature Medicine · 被引 97)
• Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study (2025 · Annals of Oncology · 被引 45)
• Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial (2025 · The Lancet · 被引 34)
• End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer (2025 · Journal of Clinical Oncology · 被引 22)
• Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial (2025 · Journal of Clinical Oncology · 被引 11)